Sonoma Pharmaceuticals (SNOA) Liabilities and Shareholders Equity (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Liabilities and Shareholders Equity of $14.0 million for Q1 2026, up 1.95% year-over-year from $13.7 million in Q1 2025, and up 2.47% quarter-over-quarter from $13.6 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $14.0 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 1.95% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $56.0 million (up 2.4% YoY), while the FY2026 annual figure was $14.0 million, up 1.95% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $14.0 million, up from $13.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $18.8 million in Q1 2022, with the low at $13.6 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $14.0 million (2026), against an average of $14.8 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 25.74% in 2022, while the deepest fall reached 28.01% in 2022.
- Sonoma Pharmaceuticals' Liabilities and Shareholders Equity stood at $13.9 million in 2022, then climbed by 4.95% to $14.6 million in 2023, then decreased by 6.5% to $13.7 million in 2024, then retreated by 0.33% to $13.6 million in 2025, then grew by 2.47% to $14.0 million in 2026.
- Business Quant data shows SNOA's Liabilities and Shareholders Equity at $14.0 million in Q1 2026, $13.6 million in Q4 2025, and $13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 18.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.11 Mn |
| Mar 31, 2026 | 13.96 Mn |
| Dec 31, 2025 | 13.62 Mn |
| Sep 30, 2025 | 13.86 Mn |
| Jun 30, 2025 | 14.59 Mn |
| Mar 31, 2025 | 13.69 Mn |
| Dec 31, 2024 | 13.67 Mn |
| Sep 30, 2024 | 13.69 Mn |
| Jun 30, 2024 | 13.67 Mn |
| Mar 31, 2024 | 14.74 Mn |
| Dec 31, 2023 | 14.62 Mn |
| Sep 30, 2023 | 13.64 Mn |
| Jun 30, 2023 | 15.89 Mn |
| Mar 31, 2023 | 16.23 Mn |
| Dec 31, 2022 | 13.93 Mn |
| Sep 30, 2022 | 14.96 Mn |
| Jun 30, 2022 | 17.16 Mn |
| Mar 31, 2022 | 18.85 Mn |
| Dec 31, 2021 | 19.35 Mn |
| Sep 30, 2021 | 19.83 Mn |